Article
Pharmacophore-based Identification of Potential Mutant Isocitrate Dehydrogenases I/2 Inhibitors: An Explorative Avenue in Cancer Drug Design.
Anti-cancer agents in medicinal chemistry - 1 Jan 2023
Poonan Preantha, Peters Xylia Q, Soliman Mahmoud E S, Alahmdi Mohamed I, Abo-Dya Nader E
Abstract excerpt
BACKGROUND: Heterozygous mutations in the cytoplasmic and mitochondrial isoforms of isocitrate dehydrogenase enzymes 1 and 2 subtypes have been extensively exploited as viable druggable targets, as they decrease the affinity of isocitrate and higher affinity of D-2-hydroxyglutarate, an oncometabolite. OBJECTIVE: Vorasidenib (AG-881) has recently been reported as a promising dual inhibitor of mutant isocitrate...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.